• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=9802058).
  

PubMed=9815701
Thompson J., Zamboni W.C., Cheshire P.J., Lutz L., Luo X.-L., Li Y.-L., Houghton J.A., Stewart C.F., Houghton P.J.
Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Clin. Cancer Res. 3:423-431(1997)

PubMed=9802058
McPake C.R., Tillman D.M., Poquette C.A., George E.O., Houghton J.A., Harris L.C.
Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status.
Oncol. Res. 10:235-244(1998)

PubMed=10933967; DOI=10.1006/mthe.2000.0064
Pawlik C.A., Iyengar R.V., Krull E.J., Mason S.E., Khanna R., Harris L.C., Potter P.M., Danks M.K., Guichard S.M.
Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11.
Mol. Ther. 1:457-463(2000)

PubMed=11306486
Iyengar R.V., Pawlik C.A., Krull E.J., Phelps D.A., Burger R.A., Harris L.C., Potter P.M., Danks M.K.
Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression.
Cancer Res. 61:3045-3052(2001)

PubMed=28350380; DOI=10.1038/sdata.2017.33; PMCID=PMC5369315
Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L., Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.
Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.
Sci. Data 4:170033-170033(2017)